November 22, 2016 - By Marguerite Chambers · 0 Comments
The stock of Intrexon Corporation (NYSE:XON) registered an increase of 0.26% in short interest. XON’s total short interest was 17.83M shares in November as published by FINRA. Its up 0.26% from 17.79 million shares, reported previously. With 1.49 million shares average volume, it will take short sellers 12 days to cover their XON’s short positions. The short interest to Intrexon Corporation’s float is 32.22%. The stock decreased 0.58% or $0.18 during the last trading session, hitting $31.01. Intrexon Corp (NYSE:XON) has declined 15.80% since April 20, 2016 and is downtrending. It has underperformed by 20.36% the S&P500.
Intrexon Corporation forms collaborations to create biologically based products and processes using synthetic biology. The company has a market cap of $3.65 billion. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. It currently has negative earnings. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.
Insitutional Activity: The institutional sentiment increased to 1.3 in Q2 2016. Its up 0.18, from 1.12 in 2016Q1. The ratio improved, as 37 funds sold all Intrexon Corp shares owned while 40 reduced positions. 18 funds bought stakes while 68 increased positions. They now own 98.85 million shares or 1.45% less from 100.31 million shares in 2016Q1.
Delta Asset Mngmt Limited Liability Corporation Tn holds 0.02% of its portfolio in Intrexon Corp (NYSE:XON) for 5,000 shares. Emerald Advisers Pa, a Pennsylvania-based fund reported 322,897 shares. Wells Fargo & Co Mn, a California-based fund reported 383,632 shares. Atlantic Trust Gp Lc has 0% invested in the company for 14,661 shares. Manufacturers Life Insur Company The accumulated 0% or 3,202 shares. Utah Retirement Sys holds 10,000 shares or 0.01% of its portfolio. Fund reported 64,927 shares or 0.01% of all its holdings. Private Wealth Prtnrs Ltd Limited Liability Company accumulated 15,500 shares or 0.09% of the stock. Da Davidson & Co holds 0% of its portfolio in Intrexon Corp (NYSE:XON) for 1,140 shares. Mount Lucas Limited Partnership, a Pennsylvania-based fund reported 3,900 shares. Fifth Third Savings Bank owns 415 shares or 0% of their US portfolio. Equitec Proprietary Ltd reported 30,733 shares or 0.03% of all its holdings. Creative Planning reported 6,975 shares or 0% of all its holdings. Brown Advisory Inc has 76,833 shares for 0.01% of their US portfolio. Susquehanna Int Ltd Liability Partnership last reported 0% of its portfolio in the stock.
Insider Transactions: Since August 29, 2016, the stock had 1 insider purchase, and 0 insider sales for $104,484 net activity. $104,484 worth of Intrexon Corp (NYSE:XON) shares were bought by Nimrodi Nir.
Out of 6 analysts covering Intrexon (NYSE:XON), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. $70 is the highest target while $28 is the lowest. The $47.40 average target is 52.85% above today’s ($31.01) stock price. Intrexon has been the topic of 10 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Wunderlich on Tuesday, August 11. The stock of Intrexon Corp (NYSE:XON) has “Neutral” rating given on Wednesday, November 11 by Mizuho. Stifel Nicolaus initiated the shares of XON in a report on Monday, September 21 with “Buy” rating. The stock of Intrexon Corp (NYSE:XON) has “Buy” rating given on Monday, October 19 by Wunderlich. As per Tuesday, August 11, the company rating was downgraded by Mizuho. JP Morgan downgraded Intrexon Corp (NYSE:XON) on Tuesday, August 11 to “Overweight” rating. Mizuho maintained Intrexon Corp (NYSE:XON) on Monday, January 25 with “Neutral” rating. The stock of Intrexon Corp (NYSE:XON) earned “Buy” rating by Wunderlich on Monday, July 27. The firm has “Market Outperform” rating given on Tuesday, May 3 by JMP Securities. The rating was initiated by Bank of America on Wednesday, October 14 with “Neutral”.
Intrexon Corporation (Intrexon), incorporated on June 1, 2010, forms collaborations to create biologically based products and processes using synthetic biology. The Company’s domestic activities are in California, Florida, Maryland, and Virginia, and its primary international activities are in Belgium and Hungary. The Firm designs, manufactures and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies combine the principles of precision engineering, statistical modeling, automation and production at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing, or LEAP, and ActoBiotics platform.
More recent Intrexon Corp (NYSE:XON) news were published by: Fool.com which released: “3 Reasons Intrexon Corp. Stock Could Rise” on November 15, 2016. Also Nasdaq.com published the news titled: “Commit To Purchase Intrexon Corp At $17.50, Earn 16.6% Using Options” on October 25, 2016. Prnewswire.com‘s news article titled: “AquaBounty Technologies Inc. (“AquaBounty” or the “Company”) Filing of Form 10 …” with publication date: November 07, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Marguerite Chambers